Klaria Pharma (Sweden) Probability of Future Stock Price Finishing Over 19.12

KLAR Stock  SEK 0.91  0.16  21.33%   
Klaria Pharma's future price is the expected price of Klaria Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Klaria Pharma Holding performance during a given time horizon utilizing its historical volatility. Check out Klaria Pharma Backtesting, Klaria Pharma Valuation, Klaria Pharma Correlation, Klaria Pharma Hype Analysis, Klaria Pharma Volatility, Klaria Pharma History as well as Klaria Pharma Performance.
  
Please specify Klaria Pharma's target price for which you would like Klaria Pharma odds to be computed.

Klaria Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Klaria Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Klaria Pharma Holding can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Klaria Pharma is way too risky over 90 days horizon
Klaria Pharma has some characteristics of a very speculative penny stock
Klaria Pharma appears to be risky and price may revert if volatility continues
Klaria Pharma Holding has accumulated 1.02 M in total debt. Klaria Pharma Holding has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Klaria Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Klaria Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Klaria Pharma Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Klaria to invest in growth at high rates of return. When we think about Klaria Pharma's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (53.53 M) with profit before overhead, payroll, taxes, and interest of 5.87 M.
Klaria Pharma Holding has accumulated about 25.49 M in cash with (24.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.

Klaria Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Klaria Stock often depends not only on the future outlook of the current and potential Klaria Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Klaria Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding51.8 M
Cash And Short Term Investments25.5 M

Klaria Pharma Technical Analysis

Klaria Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Klaria Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Klaria Pharma Holding. In general, you should focus on analyzing Klaria Stock price patterns and their correlations with different microeconomic environments and drivers.

Klaria Pharma Predictive Forecast Models

Klaria Pharma's time-series forecasting models is one of many Klaria Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Klaria Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Klaria Pharma Holding

Checking the ongoing alerts about Klaria Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Klaria Pharma Holding help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Klaria Pharma is way too risky over 90 days horizon
Klaria Pharma has some characteristics of a very speculative penny stock
Klaria Pharma appears to be risky and price may revert if volatility continues
Klaria Pharma Holding has accumulated 1.02 M in total debt. Klaria Pharma Holding has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Klaria Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Klaria Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Klaria Pharma Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Klaria to invest in growth at high rates of return. When we think about Klaria Pharma's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (53.53 M) with profit before overhead, payroll, taxes, and interest of 5.87 M.
Klaria Pharma Holding has accumulated about 25.49 M in cash with (24.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.

Additional Tools for Klaria Stock Analysis

When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.